Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Dec;65(12):1211-28.
doi: 10.1007/s00228-009-0718-4. Epub 2009 Sep 16.

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

Adedigbo A Fasanmade  1 , Omoniyi J Adedokun, Joyce Ford, Danika Hernandez, Jewel Johanns, Chuanpu Hu, Hugh M Davis, Honghui Zhou
Affiliations
Clinical Trial

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

Adedigbo A Fasanmade et al. Eur J Clin Pharmacol. 2009 Dec.

Abstract

Purpose: Infliximab, a monoclonal antibody, is approved for the treatment of inflammatory diseases at doses that depend on the patient disease population. It was the aim of this study to evaluate its population pharmacokinetics in patients with moderately to severely active ulcerative colitis and characterize patient covariates that affect its disposition in this population.

Methods: Information collected from 482 patients in two randomized, double-blind, placebo-controlled international studies were analyzed using NONMEM.

Results: A two-compartment, population pharmacokinetic model described the serum infliximab concentration-time data. Population pharmacokinetic estimates (typical value +/- standard error), based on the final covariate model, were clearance (CL: 0.407 +/- 0.0103 L/day), apparent volumes of distribution in the central (V(1): 3.29 +/- 0.0679 L) and peripheral (V(2): 4.13 +/- 0.16 L) compartments, and intercompartment clearance (Q: 7.14 +/- 0.489 L/day). Infliximab exhibited interindividual variability for CL and V(1) of 37.7% and 22.1%, respectively. Infliximab t(1/2) is approximately 14 days. Covariate analysis showed that V(1) increased as body weight increased, and CL was higher in patients who developed antibodies to infliximab. An additional novel covariate, serum albumin concentration, was found to be inversely and strongly related to infliximab clearance in this population.

Conclusions: The disposition of infliximab in patients with moderately to severely active ulcerative colitis, unlike in rheumatoid arthritis, was not affected by coadministration of immunomodulators and corticosteroids but was related to formation of antibodies to infliximab and, notably, to serum albumin levels.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Goodness-of-fit plots for the base model. Dashed lines represent the locally weighted smoothing (LOESS) of the data
Fig. 2
Fig. 2
Goodness-of-fit plots for the final model. Dashed lines represent the locally weighted smoothing (LOESS) of the data
Fig. 3
Fig. 3
Empirical Bayesian Estimates (EBEs) of V1 (panel A), clearance (CL) (panel B), and ETA2(V1) (panels C and D) versus body weight. V 1 volume of distribution in the central compartment, CL clearance, ETA2(V 1) random effect of V1
Fig. 4
Fig. 4
Empirical Bayesian estimates (EBEs) of CL (panel A), ETA1(CL) (panels B and C) versus baseline albumin. CL learance, ETA1(CL) random effect of clearance
Fig. 5
Fig. 5
Empirical Bayesian stimates (EBEs) of CL (panel A), ETA1(CL) (panels B and C) versus antibody to infliximab status. CL clearance, ETA1(CL) random effect of clearance
Fig. 6
Fig. 6
Empirical Bayesian stimates (EBEs) of CL (panel A), V1 (panel B), ETA1(CL) for base model (panel C) and ETA1(CL) for final model (panel D); ETA2(V1) for base model (panel E), and ETA2(V1) for final model (panel F) versus Sex. V 1 volume of distribution in the central compartment, CL clearance, ETA2(V 1) random effect of V1, ETA1(CL) random effect of clearance
Fig. 7
Fig. 7
Visual predictive check for representative patients shown by an overlay of individual Bayesian-estimated pharmacokinetic (PK) parameter predicted curve on the raw data: representative patients in the 5 mg/kg group in the ACT 1 (panel A);representative patients in the 10 mg/kg group in ACT 1 (panel B); representative patients in the 5 mg/kg group in the ACT 2 (panel C); representative patients in the 10 mg/kg group in the ACT 2 (panel D). Note that the dosing frequency at the beginning and early part of the study (0, 2, 6 weeks) is higher than in the later period in the study when dosing was every 8 weeks. This is reflected in the higher concentrations at early time points in the graphs
See this image and copyright information in PMC

References

    1. Remicade (infliximab) for IV injection. Malvern, Pa: Centocor Ortho Biotech, Inc., April 2009 (package insert)
    1. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354:1932–1939. doi: 10.1016/S0140-6736(99)05246-0. - DOI - PubMed
    1. Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, Dooley LT, Fasanmade A, Wagner CL. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003;48:68–75. doi: 10.1067/mjd.2003.10. - DOI - PubMed
    1. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523–529. - PubMed
    1. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46:645–660. doi: 10.2165/00003088-200746080-00002. - DOI - PubMed

Publication types